Skip to content

Workshop Day
Wednesday, November 20


Exploring Shared/Public Neoantigens to Increase the Commercial Success of Neoantigen-based Therapies
09:00 - 12:00

Patient specific neoantigen therapies pose significant practical and regulatory challenges. However, targeting shared neoantigens across patients can mean highly effective off-the-shelf cancer vaccines. Join this workshop discussion to identify where the challenges lie in targeting shared neoantigens for off-the-shelf immunotherapy.

Attendees will learn and discuss:

• Identification of shared neoantigens – approaches and data to date
• How to use shared neoantigens therapeutically
• Early clinical data – what are we learning?

Workshop Leader

Andrew Allen - Gritstone

Andrew Allen
Gritstone Therapeutics

Andrew Allen is co-founder of Gritstone Oncology, and President, CEO and a member of the BoD since August 2015. Previously he co-founded and was CMO at Clovis Oncology (NASDAQ: CLVS), and prior to that was CMO at Pharmion (acquired by Celgene in 2008 for $2.9B). He trained in Medicine at Oxford University, obtained a PhD in Immunology at Imperial College, and worked for several years at McKinsey & Company. He serves on the BoD of Epizyme (NASDAQ:EPZM), Sierra Oncology (NASDAQ:SRRA) and Revitope (private). He served on the BoD of Cell Design Labs, Inc until acquisition by Gilead in Dec 2017.


Improving Clinical Efficacy Through Immunotherapy Combinations
13:00 - 16:00

Combinations of neoantigen-specific vaccines or adoptive cell therapies are promising to overcome the immunosuppressive mechanisms of the tumor microenvironment and improve immune responses. Clinical trials will determine the most effective combinations for tumor types.

Attendees will learn and discuss:

• How to identify biomarkers of clinical response

• Efficacy of cancer vaccines with immune checkpoints in various indications

• Optimize clinical trial design to provide meaning